Aim: Older patients with chronic hepatitis C have a lower virological response to interferon (IFN)-based treatments compared to younger patients. A single nucleotide polymorphism in the IFN-λ-4 (IFNL4) gene has a potent predictive effect on treatment response to IFN-based treatments. The efficacy of simeprevir (SMV) plus pegylated-IFN (PEG-IFN) and ribavirin therapy and the predictive value of IFNL4 on the outcome of therapy for older patients have not been addressed.
INTRODUCTION
H EPATITIS C VIRUS (HCV) infection is major cause of liver disease and poses a public health threat worldwide. A distinct concern is the anticipated rise in the incidence of long-term complications, including cirrhosis, hepatocellular carcinoma (HCC), and portal hypertension, 1, 2 which are associated with increased mortality rates. 3, 4 The goal of HCV therapy is successful eradication of the virus and resolution of liver disease. The population of Japanese HCV carriers tends to be older, 5 and this is an impending problem in other countries to which HCV has spread more recently. 6 Aging is a critical risk factor for the development of HCC. 7 The progression rates of liver fibrosis and extrahepatic manifestations are more rapid in older patients. 7, 8 Although HCV infection is a significant threat to the health of older patients, treatment of older patients with interferon (IFN)-based therapy is also associated with a lower sustained virological response (SVR) rate and a higher withdrawal rate from treatment compared to younger patients. 9, 10 Although both of the two first-generation, first-wave non-structural (NS)3/4 protease inhibitors, telaprevir and boceprevir, significantly improved SVR rates when used in combination with pegylated-IFN (PEG-IFN) and ribavirin (RBV) in patients infected with HCV genotype 1, these agents require multiple daily dosing, and incur a high risk of adverse events including anemia, rash, and renal dysfunction. [10] [11] [12] Simeprevir (SMV) is a once-daily, oral HCV NS3/4 A protease inhibitor, with potent antiviral activity and lower risk of adverse events. 13 Addition of SMV has been reported to improve the SVR rate compared to PEG-IFN/RBV treatment in patients infected with HCV genotype 1. [14] [15] [16] [17] Several genome-wide association studies reported that single nucleotide polymorphisms (SNPs), especially rs12979860, upstream of the interleukin-28B (IL28B) gene encoding IFN-λ-3 (IFNL3), were strongly associated with response to IFN-based therapy and spontaneous HCV clearance. [18] [19] [20] It was later shown that the TT genotype in the ss469415590 SNP in the newly discovered IFN-λ-4 (IFNL4) gene is more strongly associated with treatmentinduced response and spontaneous HCV clearance than rs12979860 in Europeans and Asians, but especially in individuals of African ancestry. 10, 21 A dinucleotide polymorphism that introduces a frameshift was reported to affect the expression of IFNL4, a new member of the type III IFN family. IFNL4 encodes a protein similar to IFNL3, which leads to phosphorylation of signal transducer and activator of transcription 1 and 2, resulting in activation of multiple IFN-stimulated genes. 21, 22 Consequently, this SNP may impair HCV eradication.
In this study, we assessed the efficacy and safety of the IFNL4 polymorphism on SMV plus PEG-IFN/RBV triple therapy in older Japanese patients.
METHODS

Study patients
T HIS STUDY IS a retrospective analysis of 234 consecutive patients with chronic HCV treated with SMV plus PEG-IFN/RBV at the Hiroshima University Hospital (Hiroshima, Japan) and hospitals belonging to the Hiroshima Liver Study Group, carried out between December 2013 and December 2014. All 234 patients met the following inclusion criteria; diagnosis of genotype 1 chronic hepatitis C, age 20 years or above, and Japanese ethnicity. The exclusion criteria were as follows: hepatitis B or HIV coinfection, cirrhosis, HCC, or other forms of liver disease, depression, or immunodeficiency.
Patients were classified according to response to prior IFN therapy. Non-responders never became HCV RNAnegative during prior IFN therapy, whereas relapsers became HCV RNA-negative before the end of treatment but reverted to being HCV RNA-positive after treatment was discontinued.
All subjects gave written informed consent to participate in the study according to the process approved by the ethical committee of each hospital and conforming to the ethical guidelines of the 1975 Declaration of Helsinki.
Measurement of HCV RNA
Hepatitis C virus RNA levels were measured using COBAS TaqMan HCV test (Roche Diagnostics, Tokyo, Japan). The detection limit for the assay was 1.2 log IU/mL. The HCV genotype was determined by sequence determination in the 5′-non-structural region of the HCV genome followed by phylogenetic analysis. Amino acid substitutions at position 70 in the HCV core protein (core70) were analyzed by direct sequencing of polymerase chain reaction products after extraction and reverse transcription of HCV RNA as in Akuta et al.
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Determination of SNP genotype
Samples were genotyped using the Illumina HumanHap610-Quad Genotyping BeadChip or with the Invader or TaqMan assays (The Institute of Physical and Chemical Research [RIKEN], Hiroshima, Japan), as described previously. 24 Genotyping data were subjected to quality control prior to analysis. In this study, three polymorphisms were investigated: ss469415590 in the IFNL4 locus and rs8099917 near the IL28B locus, which are associated with treatment efficacy; and rs1127354, an inosine triphosphate pyrophosphate SNP reported to be associated with RBV-induced anemia. 25, 26 
Therapeutic protocol
All patients received 100 mg SMV once daily (Sovriad; Janssen Pharmaceutical K.K., Tokyo, Japan) in combination with PEG-IFNα-2a (Pegasys; Chugai Pharmaceutical, Tokyo, Japan) and RBV (Copegus; Chugai Pharmaceutical) or PEG-IFNα-2b (Pegintron; MSD, Tokyo, Japan) and RBV (Rebetol; MSD) for the first 12 weeks, followed by PEG-IFN/RBV alone for a further 12 weeks. Seven patients were judged by the attending physician to require an additional 24 weeks of PEG-IFN/RBV therapy because they remained HCV RNA-positive 8 weeks after the start of triple therapy. Pegylated-IFNα-2a was given s.c. once a week at a dose of 180 μg/body in 8 patients (3.4%) and PEG-IFNα-2b was given at a median dose of 1.5 μg/kg (range, 1.0-1.8 μg/kg) in 226 patients (96.6%). The RBV dose was adjusted by body weight (600 mg for <60 kg; 800 mg for 60-80 kg; and 1000 mg for >80 kg), with a median dose of 11.2 mg/kg/day (range, 3.0-15.5 mg/ kg). Each drug was discontinued or its dose reduced as necessary at the discretion of the attending physician, according to the manufacturer's recommendations.
Efficacy of treatment
Sustained virological response was defined as undetectable serum HCV RNA at 24 weeks after the end of treatment. Rapid virological response (RVR) was defined as undetectable HCV RNA at week 4 of treatment.
Statistical analysis
Continuous variables were presented as median and range and were analyzed using the Mann-Whitney U-test. Categorical variables were compared using the χ 2 -test or Fisher's exact test, as appropriate. Univariate and multivariate logistic regression analysis was used to identify factors that significantly contributed to SVR. The odds ratios (OR) and 95% confidence intervals were also calculated. All P-values < 0.05 in two-tailed tests were considered significant. A stepwise backward selection method (P < 0.05 with loglikelihood test for removal from the model) was used in the multivariate logistic regression analysis. All analyses were carried out using IBM SPSS Statistics 22 software (IBM SPSS, Inc., Chicago, IL, USA). The G*power program 27 was used to calculate type II error and to estimate the sample size required to detect the differences between groups.
RESULTS
Baseline patient characteristics P ATIENTS WERE GROUPED according to age (younger: <70 years, n = 170; older: ≥70 years, n = 64) in Table 1 . Aspartate aminotransferase, alanine aminotransferase, γ-glutamyl transpeptidase, and α-fetoprotein (AFP) levels were significantly lower in older patients than in younger patients. The older group included 28 treatment-naïve patients, 16 prior relapsers, and 20 previous non-responders. The younger group included 92 treatment-naïve patients, 43 prior relapsers, and 30 previous non-responders.
Sustained virological response by age
The SVR rate for older patients was similar to that for younger patients (63.9% and 72.0%, respectively). Sustained virological response was more likely to be achieved in treatment-naïve patients and prior relapsers than in prior non-responders in both younger (78.6% and 36.7%, respectively, P < 0.001) and older patients (78.6% and 31.6%, respectively, P = 0.001) (Fig. 1) .
Predictive factors associated with SVR in older and younger patients
In older patients, significant univariate predictors for SVR included IFNL4 genotype, IL28B genotype, response to previous treatment, albumin levels, AFP, and RVR (Table 2) . Multivariate logistic regression analysis was carried out using these variables, and IFNL4 TT/TT genotype (odds ratio [OR], 41.291 for TT/ G + G/ G genotype; P = 0.005) and response to previous treatment (OR, 11.866 for non-responders; P = 0.043) were identified as a significant independent predictive factors for SVR for older patients. In younger patients, significant univariate predictors for SVR included IFNL4 genotype, IL28B genotype, response to previous therapy, platelet count, total cholesterol levels, AFP levels, level of viremia, core70 amino acid substitutions, adherence to SMV, adherence to PEG-IFN, adherence to RBV, completion/discontinuation of the treatment, and RVR. Multiple logistic regression analysis identified IFNL4 TT/TT genotype (OR, 283.755 for TT/ G + G/ G genotype; P = 0.006) as a significant independent predictive factor for SVR (Table 3) .
Effect of response to previous IFN treatment and IFNL4 genotype in older patients
We assessed the relationship between IFNL4 genotype and SVR in older patients. Patients with IFNL4 TT/TT genotype were significantly more likely to achieve SVR compared to those with TT/ΔG or ΔG/ΔG genotypes (84.4% and 33.3%, respectively, P < 0.001) ( Table 2) . With respect to the response to previous IFN treatment, the SVR rate was significantly higher in IFNL4 patients with TT/TT genotype compared to TT/ΔG or ΔG/ΔG genotypes in treatmentnaïve patients and prior relapsers (88.5% and 50.0%, respectively, P < 0.001) (Fig. 2) . Although 66.6% of treatment-naïve patients and prior relapsers achieved SVR, none of six prior non-responders who had IFNL4 TT/ΔG or ΔG/ΔG genotypes achieved SVR. Similar to older patients, younger patients with the IFNL4 TT/TT genotype were significantly more likely to achieve SVR compared to those with TT/ΔG or ΔG/ΔG genotypes (93.6% and 46.1%, respectively, P < 0.01) ( Table 3) .
Adverse events
The most frequent adverse events leading to dose reduction or discontinuation were anemia, thrombocytopenia, and general fatigue (43.7%, 8.1%, and 7.2%, respectively). Figure 3 shows the time course of hemoglobin levels grouped by age during the treatment. The hemoglobin levels before treatment were not significantly different between younger and older patients. Although reduction of hemoglobin levels at week 2 of treatment was greater in older patients than younger patients, hemoglobin levels after week 4 of the treatment were similar. Frequencies of patients whose hemoglobin level decreased to less than 10.0 g/dL during the therapy were similar between younger and older patients (47.1% and 51.6%, respectively). The frequencies of hyperbilirubinemia of more than 2 mg/dL, identified as grade 2 on the World Health Organization's Toxicity Grading Scale, were also similar between younger and older patients (26.1% and 27.8%, respectively). Thirty patients (12.8%) discontinued the therapy due to adverse events such as anemia (11 patients, 4.7%), depression (4 patients, 1.7%), thrombocytopenia (2 patients, 0.9%), fatigue (2 patients, 0.9%) and other causes (11 patients, 4.7%). The incidence of treatment discontinuation tended to be higher in older patients compared to younger patients (18.8% [12 out of 64 patients] and 10.6% [18 out of 170 patients], respectively). The ratio Categorical data are represented as numbers of patients, and continuous data is represented as median (range). Core70, hepatitis C virus core protein amino acid; ND, not determined; PR, peginterferon with rivabirin combination therapy.
of patients who had greater than 80% adherence to PEG-IFN (74.5% and 72.1%, respectively) and SMV (91.8% and 88.3%, respectively) were similar between younger and older patients. By contrast, the ratio of patients who received more than 80% of the planned RVB dosage was significantly lower in the older group compared to the younger group (24.6% and 55.1%, respectively, P < 0.001).
DISCUSSION
A LTHOUGH TELAPREVIR SIGNIFICANTLY improved SVR rates when used in combination with PEG-IFN/ RBV in genotype 1 chronic hepatitis C patients, the agent was associated with several adverse events, especially in older patients. We previously reported that adverse events such as anemia and renal dysfunction during telaprevir plus PEG-IFN/RBV therapy were more serious and SVR rates were lower in older patients compared to younger patients. 10 In contrast to telaprevir, however, the present study showed that older patients had a similar treatment response and a similar tolerance for SMV plus PEG-IFN/ RBV therapy to younger patients.
The overall SVR rate (70%) in the present study was lower compared to phase 3 clinical trials of SMV plus PEG-IFN/RBV therapy in Japan. [15] [16] [17] The treatment discontinuation rate in the present study, in which 30 patients (12.8%) discontinued therapy due to adverse events, was higher than that in the phase 3 clinical trial CONCERTO-1 (7.3%). 15 The low SVR rate in the present study may be partly due to the inclusion of 50 patients (21.4%) who were non-responders to prior therapy in this study. Although poor response to SMV plus PEG-IFN/RBV therapy was expected in these patients, they agreed to undergo therapy in consideration of sustained high alanine aminotransferase levels and a high risk of the development of HCC instead of deferring treatment.
The main adverse event in the present study was anemia. Decreases in hemoglobin levels during treatment and frequencies of patients in whom hemoglobin levels decreased to less than 10.0 g/dL during therapy did not differ with respect to age. Severe anemia, in which the hemoglobin level decreased to less than 8.0 g/dL, was observed in five patients (2.1%), two of whom were younger patients and three of whom were older. Although adherence to PEG-IFN and SMV were similar by age, adherence to RBV was significantly lower in older patients than in younger patients (61.7 ± 33.3% vs 75.4 ± 33.5%, P = 0.003). High frequencies of RBV dose reduction in older patients might correspond to increased rates of anemia in younger patients.
Multivariate logistic regression analysis identified IFNL4 TT/TT genotype as an independent predictor for SVR for both younger and older patients. Single nucleotide polymorphism ss469415590 in the IFNL4 gene is strongly associated with HCV clearance through both the innate immune reaction as well as through PEG-IFN plus RBV therapy. 21 IFNL4 genotype is also an important predictor of the probability of eradicating the virus by telaprevir plus PEG-IFN/RBV therapy. 10 In the present study, while the SVR rate among older patients with IFNL4 genotype TT/TT was 84.4%, patients with IFNL4 TT/ΔG or ΔG/ΔG genotypes, especially among non-responders to prior therapy, had poor response, indicating that IFNL4 genotype is an important predictor of SVR by SMV plus PEG-IFN/RBV therapy. IFNL4 SNP ss469415590 is in strong linkage disequilibrium with IL28B SNPs rs8099917 and rs12979860, especially in Asian populations. 21 In the present study, 6 out of 187 patients (3.2%) showed discrepant haplotypes; all 6 patients had ss469415590 TT/TT and rs12979860 TG genotypes. Further analysis with larger numbers of patients is needed to determine whether rs8099917 or ss469415590 is more important for prediction of the treatment response. In the present study, univariate logistic regression analysis showed a stronger association of SVR with the IFNL4 SNP compared with the IL28B SNP for both younger and older patients. These results are compatible with previous reports showing that the IFNL4 SNP was similar or more strongly associated with response to PEG- Figure 1 Rates of sustained virological response 24 weeks after the end of therapy for Japanese patients with genotype 1 chronic hepatitis C treated with simeprevir, pegylated interferon, and ribavirin. Patients were grouped by response to prior interferon treatment and age (younger group, <70 years; older group, ≥70 years). n.s., not significant. CI, confidence interval; Core70, hepatitis C virus core protein amino acid; ND, not determined; OR, odds ratio. 
<0.001
Categorical data are represented as numbers of patients, and continuous data is represented as median (range).
CI, confidence interval; Core70, hepatitis C virus core protein amino acid; ND, not determined.
Simeprevir Figure 2 Relationship between treatment reponse and IFNL4 genotype in older Japanese patients with genotype 1 chronic hepatitis C. Sustained virological response rates for triple therapy grouped by response to prior interferon treatment and ss469415590 genotype (TT/TT and TT/ΔG or ΔG/ΔG). n.s., not significant. Figure 3 Reduction of hemoglobin levels in Japanese patients with genotype 1 chronic hepatitis C treated with simeprevir, pegylated interferon, and ribavirin, grouped by age. *P < 0.05.
